top of page

Click to Download


Wednesday, 4 October 2023

Press Release

Media Contacts:

IB Communications

Tel +44 (0)20 89434685

CTMC partners with ScaleReady to automate, close, and scale for greater patient accessibility

St. Paul, MN and Houston, TX, US, October 4, 2023 — ScaleReady, the cell therapy manufacturing solutions expert, and CTMC, a joint venture between National Resilience Inc. and MD Anderson Cancer Center, today announces a collaborative partnership to help lessen the manufacturing barriers holding back life-saving cell and gene therapies from reaching more patients by integrating cutting-edge automation tools. The agreement will enable CTMC to strategically scale the recently completed GMP facility to drive high-throughput manufacturing utilizing the automated, closed system capabilities of the Fresenius Kabi Lovo(R) and Cue(R) cell processing systems.

“CTMC sees tremendous value in using products with a solid track record of clinical and commercially approved cell therapy successes. ScaleReady’s expertise and platform access will help us to leverage innovative technologies, like the Lovo, for our cell therapy process,” said Laine Linden, Head of CTMC Technical Operations. “With the addition of the Fresenius Kabi Cue to our manufacturing platform, we hope to drive down variability and increase the number of patients we can successfully treat by automating and closing the final fill and finish steps of our cell therapy products.”

“We are honored to partner with CTMC and support their work to commercialize therapies from some of the world's leading cancer experts. By providing this state-of-the-art facility and their technical experts with the Cue system, we can functionally close the critical final fill and finish steps, which have historically been manual and open processes,” said Josh Ludwig, global commercial director ScaleReady. “This leading-edge technology brings a new level of automation and scalability. Our expanded partnership with CTMC will significantly impact not only the research and the organization but also the patients in need of life-saving therapies.”

About ScaleReady

ScaleReady is bringing the future of cell and gene therapies to life with its powerful and versatile manufacturing platform. ScaleReady delivers rapid expansion of immune cells at any scale—reducing complexity and cost while providing superior repeatability and cell quality. Founded in 2020, ScaleReady is a joint venture of Bio-Techne, Fresenius Kabi, and Wilson Wolf that brings together tools and technologies for cell culture, cell activation, gene editing, and cell processing from each founding partner. Learn more at

About CTMC

CTMC – a joint venture between MD Anderson Cancer Center and Resilience – was created to accelerate the development and manufacturing of impactful cell therapies for patients with cancer. Our strategic position within the Texas Medical Center, combined with our expertise in TIL and CAR-T development, manufacturing, and regulatory, converge to enable an accelerated path to IND for cell therapies. By leveraging the strengths of MD Anderson and Resilience, we start clinical trials faster and provide a clear path to robust commercialization. Follow us @ctmc on LinkedIn and visit our website at

About the Fresenius Kabi Lovo and Cue Cell Processing Systems

ScaleReady seamlessly integrates cell-based therapy manufacturing platforms for therapeutics developers and contract manufacturers. This includes access to the Fresenius Kabi Lovo Automated Cell Processing System, for scalable cell processing, and Cue Small Volume Cell Processing System, for automated fill and finish. The Lovo Cell Processing System and Cue Cell Processing System are for laboratory use only and may not be used for direct transfusion. Appropriate regulatory clearance is required by the user for clinical use. Refer to the Lovo and Cue Cell Processing System Operator’s Manuals for a complete list of warnings and precautions associated with the use of these products.

bottom of page